Gold prices slid below $4,000/oz amid profit-taking on Gaza ceasefire
ResMed (NASDAQ:RMD) Chief Executive Officer Michael J. Farrell sold 8,009 shares of company stock on October 7, 2025, for approximately $2.26 million. The sales were executed in multiple trades at prices ranging from $280.95 to $283.90. The stock, which has gained 31% over the past six months, is currently trading near its 52-week high of $293.81. According to InvestingPro analysis, ResMed appears slightly undervalued at current levels.
On the same day, Farrell exercised options to acquire 8,009 shares of ResMed common stock at a price of $101.64, for a total value of $814,034. These options became exercisable beginning November 11, 2019, and vest in increments of one-third per year. ResMed maintains strong financial health with a "GREAT" rating from InvestingPro, which offers comprehensive analysis of 1,400+ stocks through its Pro Research Reports.
Following these transactions, Farrell directly owns 467,792 shares of ResMed. Additionally, he indirectly owns 2,090 shares through the Lisette and Michael Farrell Family Trust. The company, currently valued at $40.86 billion, offers a dividend yield of 0.85% and has maintained dividend payments for 14 consecutive years.
In other recent news, ResMed Inc . reported its fourth-quarter earnings for fiscal year 2025, surpassing earnings per share (EPS) expectations with an EPS of $2.55, compared to the forecast of $2.48. However, the company’s revenue fell short of projections, reaching $1.3 billion against the expected $1.33 billion. Despite a 23% increase in non-GAAP diluted EPS and a 10% rise in group revenue, the company’s stock experienced a slight decline post-earnings call. In related developments, UBS reiterated its Buy rating and maintained a $325.00 price target on ResMed, emphasizing the impact of GLP-1 medication usage among sleep apnea patients. KeyBanc also reiterated its Overweight rating with a $298.00 price target, expressing confidence in ResMed’s financial trajectory. Additionally, ResMed was affected by a U.S. Commerce Department investigation into medical equipment, alongside other major medical device manufacturers. This investigation has created uncertainty in the sector, as noted by Needham. These developments provide important insights for investors monitoring ResMed’s performance and market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.